{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1383670319347355397.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Amarnath Sharma"}],"foaf:familyName":[{"@value":"Sharma"}],"foaf:givenName":[{"@value":"Amarnath"}]}],"career":[{"institution":{"notation":[{"@value":"From the Departments of Medicine, Division of Hematology/Oncology; Surgery, Division of Surgical Oncology and UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Departments of Experimental Therapeutics, Melanoma Medical Oncology and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Pfizer Global Research and Development, Groton-New London, CT"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1363670319347355520","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1200/jco.2005.01.109"},{"@type":"URI","@value":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.01.109"},{"@type":"NAID","@value":"30022790545"}],"notation":[{"@value":"Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1200/jco.2005.01.109_E6i5DcBhlXiUGvUOhRyQ4xfVD1f"}]}